睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Pucotenlimab and Anlotinib in Combination With Chemotherapy

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由浙江省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07896668,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed invasive breast carcinoma with documented ER-negative, PR-negative, and HER2-negative status, defined as:

    入选标准第 3 条

  3. Clinical stage II-III per AJCC 8th edition and at least one measurable lesion per RECIST v1.1.

    入选标准第 8 条

    NYHA class < 3;

    入选标准第 19 条

  4. **Female patients**: surgically sterile, postmenopausal, or agree to use at least one medically approved contraceptive measure (e.g., IUD, oral contraceptives, condoms) during and for 6 months after the treatment period; negative serum/urine pregnancy test within 7 days prior to enrollment; not lactating.

    入选标准第 23 条

    **Male patients**: agree to use at least one medically approved contraceptive measure (e.g., condom, abstinence) during and for 6 months after the treatment period.

    入选标准第 24 条

  5. ECOG performance status 0-1.

    入选标准第 10 条

  6. Absolute neutrophil count ≥ 1.5 × 10⁹/L;

    入选标准第 12 条

    Platelet count ≥ 100 × 10⁹/L;

    入选标准第 13 条

    Hemoglobin ≥ 90 g/L;

    入选标准第 14 条

    Total bilirubin ≤ 1.5 × ULN;

    入选标准第 15 条

    AST, ALT, and ALP ≤ 2.5 × ULN;

    入选标准第 16 条

    Serum creatinine ≤ 1.5 × ULN or creatinine clearance (Cockcroft-Gault formula) ≥ 50 mL/min.

    入选标准第 17 条

  7. History of invasive malignancy ≤ 5 years prior to informed consent, except adequately treated basal/squamous cell skin cancer or in situ cervical cancer.

    排除标准第 2 条

    HBV carriers or patients stabilized on antiviral therapy with HBV DNA ≤ 500 IU/mL or < 2500 copies/mL are allowed.

    排除标准第 13 条

    Active hepatitis C defined as positive anti-HCV antibody with quantifiable HCV RNA above the lower limit of detection.

    排除标准第 14 条

    HIV positive;

    排除标准第 16 条

  8. Pregnant or lactating female patients.

    排除标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07896668,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary participation and signed informed consent.
  2. Age ≥ 18 years, male or female.
  3. Histologically confirmed invasive breast carcinoma with documented ER-negative, PR-negative, and HER2-negative status, defined as:
  4. ER and PR: nuclear staining < 10% by IHC;
  5. HER2: 0 or 1+ by IHC, or 2+ with negative FISH amplification.
  6. Known PD-L1 status.
  7. Assessed by breast surgeon as eligible and planned for radical mastectomy.
  8. Clinical stage II-III per AJCC 8th edition and at least one measurable lesion per RECIST v1.1.
  9. No prior systemic therapy for the current disease, including surgery, radiotherapy, chemo/immunotherapy, etc.
  10. ECOG performance status 0-1.
  11. Adequate hematologic and organ function, as defined by:
  12. Absolute neutrophil count ≥ 1.5 × 10⁹/L;
  13. Platelet count ≥ 100 × 10⁹/L;
  14. Hemoglobin ≥ 90 g/L;
  15. Total bilirubin ≤ 1.5 × ULN;
  16. AST, ALT, and ALP ≤ 2.5 × ULN;
  17. Serum creatinine ≤ 1.5 × ULN or creatinine clearance (Cockcroft-Gault formula) ≥ 50 mL/min.
  18. Adequate cardiac function:
  19. NYHA class < 3;
  20. Left ventricular ejection fraction (LVEF) ≥ 50%.
  21. Life expectancy ≥ 3 months.
  22. Contraceptive requirements:
  23. **Female patients**: surgically sterile, postmenopausal, or agree to use at least one medically approved contraceptive measure (e.g., IUD, oral contraceptives, condoms) during and for 6 months after the treatment period; negative serum/urine pregnancy test within 7 days prior to enrollment; not lactating.
  24. **Male patients**: agree to use at least one medically approved contraceptive measure (e.g., condom, abstinence) during and for 6 months after the treatment period.
  25. Willing and able to comply with study visits, procedures, prohibitions, and restrictions specified in the protocol.

排除标准:Exclusion Criteria:

  1. Stage IV (metastatic) TNBC.
  2. History of invasive malignancy ≤ 5 years prior to informed consent, except adequately treated basal/squamous cell skin cancer or in situ cervical cancer.
  3. Prior systemic anticancer therapy (including investigational agents) before planned start of study treatment.
  4. Known hypersensitivity to pucotenlimab, nab-paclitaxel, or any of their components.
  5. Active or history of autoimmune disease with potential for relapse (e.g., SLE, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis) or high risk (e.g., organ transplant requiring immunosuppressive therapy). **Exceptions allowed for**:
  6. Type I diabetes mellitus stabilized on fixed insulin regimen;
  7. Autoimmune hypothyroidism on hormone replacement therapy only;
  8. Skin conditions not requiring systemic therapy (e.g., eczema, rash involving < 10% BSA, psoriasis without ocular symptoms).
  9. Major surgery, open biopsy, or significant trauma within 4 weeks prior to planned start of study treatment. Major surgery defined as requiring at least 3 weeks of recovery before study treatment.
  10. History of allogeneic organ or hematopoietic stem cell transplantation.
  11. Pregnant or lactating female patients.
  12. Untreated acute/chronic active hepatitis B or hepatitis C infection. **Exceptions**:
  13. HBV carriers or patients stabilized on antiviral therapy with HBV DNA ≤ 500 IU/mL or < 2500 copies/mL are allowed.
  14. Active hepatitis C defined as positive anti-HCV antibody with quantifiable HCV RNA above the lower limit of detection.
  15. Uncontrolled concurrent illness, including but not limited to:
  16. HIV positive;
  17. Active or poorly controlled severe infection;
  18. Severe or uncontrolled systemic disease (e.g., severe psychiatric/neurological disorders, epilepsy/dementia, unstable or uncompensated respiratory, cardiovascular, hepatic, or renal disease);
  19. Unstable systemic disease such as diabetes (fasting glucose ≥ 10 mmol/L) or hypertension (systolic BP > 150 mmHg or diastolic BP > 90 mmHg).
  20. Active bleeding or new thrombotic disease on therapeutic anticoagulation, or bleeding diathesis.
  21. Active tuberculosis.
  22. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation.

引自 ClinicalTrials.gov, NCT07896668, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07896668,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07896668